Leadership and Administration Core

领导和行政核心的目标是确保POCRC的翻译目标是 并确保资源得到有效利用。领导核心负责持续评估 所有项目的科学和翻译进展。如果进展不充分，执行委员会 由首席调查员Nicole Urban博士和联合首席调查员Mary(Nora)Disis博士组成， 查尔斯·德雷舍尔、贝丝·卡兰、史蒂夫·柯林斯和马丁·切弗将采取必要的行动。这个 执行委员会还负责确保核心满足项目的需要 冗余或保密，提供科学的领导，促进孢子间的沟通，协调 合作，整合POCRC和CCSG的活动，并分配孢子资源。 领导核心将负责协调孢子活动并确保沟通 在核心、项目和委员会之间。领导核心内的委员会将包括 患者代言人小组成员的陈述，以确保POCRC的一致性 致力于实现其翻译目标并满足患者的需求。领导核心 将在已建立的基础上，为孢子的翻译活动提供全面指导 跨学科协作。它将促进、监督和评估核心之间的积极交互 还有那些项目。通过咨询委员会，领导核心将提供 以下职能：1)孢子的全面管理和协调；2)满足科学咨询 个人研究项目的需求；3)监督、计划和评估孢子研究项目，包括 孢子活动；4)促进、监督和评估核心和项目的互动；5)鼓励、选择、 和指导发展项目；6)提供指导和职业发展；7)管理、分发和 酌情重新分配孢子基金和其他资源；8)监督内部审查委员会的活动；9)确保 科学目标最终可以转化为病人护理；10)发起新的活动，以应对 重要的翻译研究机会。 为了满足项目和核心的需求，卵巢癌专家、转化性研究、早期 检测/筛查、流行病学、基因组学、免疫学、统计学方法、信息学和病理学 已被确定并被招募到领导核心部门服务。具有相关专业知识的高级领导 将在实质性委员会中相互交流，并为POCRC提供指导 调查人员是各自领域的专家，但对其他学科不太熟悉 卵巢癌转化研究的职业发展和POCR(Z；)的总体成功。 相关性(请参阅说明)： 这种卵巢孢子的目的是展示1)筛选高危女性的更好策略。 新的血清标志物和最先进的成像技术，无需另一项大型试验，通过整合我们的 第一阶段试验结果和正在进行的第三阶段疗效试验的报告；2)选择妇女接受新辅助治疗 通过检测她们的血液是否具有可切除性特征来进行治疗；以及3)让女性对自己的血液进行免疫 以防止肿瘤复发。这些努力中的一项或多项取得成功将显著减轻 卵巢癌。

The goal of the Leadership and Administration Core is to ensure that translational goals of the POCRC are met and that resources are used effectively. The Leadership Core is responsible for ongoing evaluation of scientific and translational progress of all projects. If progress is not sufficient, the Executive Committee comprised of Dr. Nicole Urban, Principal Investigator, and co-principal investigators, Drs. Mary (Nora) Disis, Charles Drescher, Beth Karlan, Steve Collins, and Martin (Mac) Cheever, will take necessary action. The Executive Committee is also responsible for ensuring that cores meet the needs of projects without redundancy or confiict, providing scientific leadership, facilitafing Inter-SPORE communication, coordinafing collaborations, integrating POCRC and CCSG activities, and allocating SPORE resources. The,Leadership Core will be responsible for coordinating SPORE activities and assuring communication between the cores, projects and committees. Committees within the Leadership Core will include representation from members ofthe Patient Advocate Group to make certain that the POCRC constanfiy works towards achieving its translational goals and meeting the needs ofthe patient. The Leadership Core will provide overall guidance for the translational activities ofthe SPORE, building on established interdisciplinary collaborations. It will promote, oversee, and evaluate active interaction between the cores and the projects. Through the advisory boards and committees, the Leadership Core will provide the following functions: 1) overall management and coordination ofthe SPORE; 2) meet the scientific advisory needs of the individual research projects; 3) oversee, plan, and evaluate SPORE acfivifies including inter¿ SPORE activities; 4) promote, oversee, and evaluate interaction of cores and projects; 5) encourage, select, and guide developmental projects; 6) provide mentoring and career development; 7) manage, distribute, and re-allocate SPORE funds and other resources as appropriate; 8) oversee IRB activity; 9) ensure that scientific objectives can ultimately be translated to patient care; 10) initiate new activities in response to important translational research opportunities. To address the needs of the projects and the cores, experts in ovarian cancer, translational research, early detection/screening, epidemiology, genomics, immunology, statistical methods, informatics, and pathology have been identified and recruited to serve in the Leadership Core. Senior leaders with relevant expertise will interact with each other on substantive committees as well as provide mentorship to POCRC investigators who are experts in their own fields but less acquainted with other disciplines that are critical to career development in ovarian cancer translational research and the overall success ofthe POCR(Z;. RELEVANCE (See instructions): The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase I trial results with reports from ongoing Phase III efficacy trials; 2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature; and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.